Tejada, M.Á.; Santos-Llamas, A.I.; Fernández-Ramírez, M.J.; Tarín, J.J.; Cano, A.; Gómez, R.
A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment. Biomedicines 2021, 9, 269.
https://doi.org/10.3390/biomedicines9030269
AMA Style
Tejada MÁ, Santos-Llamas AI, Fernández-Ramírez MJ, Tarín JJ, Cano A, Gómez R.
A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment. Biomedicines. 2021; 9(3):269.
https://doi.org/10.3390/biomedicines9030269
Chicago/Turabian Style
Tejada, Miguel Á., Ana I. Santos-Llamas, María José Fernández-Ramírez, Juan J. Tarín, Antonio Cano, and Raúl Gómez.
2021. "A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment" Biomedicines 9, no. 3: 269.
https://doi.org/10.3390/biomedicines9030269
APA Style
Tejada, M. Á., Santos-Llamas, A. I., Fernández-Ramírez, M. J., Tarín, J. J., Cano, A., & Gómez, R.
(2021). A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment. Biomedicines, 9(3), 269.
https://doi.org/10.3390/biomedicines9030269